Effects of the angiotensin‐receptor neprilysin inhibitor on cardiac reverse remodeling: meta‐analysis
Y Wang, R Zhou, C Lu, Q Chen, T Xu… - Journal of the American …, 2019 - Am Heart Assoc
Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …
[HTML][HTML] Real-world effectiveness and safety of sacubitril/valsartan in heart failure: a systematic review
C Proudfoot, R Studer, T Rajput, R **dal… - International journal of …, 2021 - Elsevier
Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …
Reverse cardiac remodeling and ARNI therapy
Abstract Purpose of Review To review reverse cardiac remodeling and guideline-directed
medical and device therapy (GDMT) within the context of recent data on combined …
medical and device therapy (GDMT) within the context of recent data on combined …
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with
heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) …
heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) …
ARNI Versus Perindopril for Remodeling in HFrEF. A Cohort Study
NMAS Bin Atan, MF Bin Hadi… - Journal of …, 2023 - journals.sagepub.com
Introduction: Ventricular remodeling is a mal-adaptive process. Both angiotensin-converting
enzyme inhibitors and sacubitril/valsartan have been shown to reverse remodeling in mostly …
enzyme inhibitors and sacubitril/valsartan have been shown to reverse remodeling in mostly …
Effect of modern versus standard of care anti-failure medications on left ventricular function in heart failure patients with reduced ejection fraction as detected by2D …
A Mamdouh Abdin, W Mohamed Attia… - Al-Azhar Medical …, 2021 - amj.journals.ekb.eg
Background: Heart failure (HF) is a major and growing public health problem, as 21 million
adults worldwide are living with heart failure and this number is expected to rise due to …
adults worldwide are living with heart failure and this number is expected to rise due to …
[PDF][PDF] Delayed left ventricular remodelling and optimal medical therapy in patients with heart failure with reduced ejection fraction. A systematic review
LW Whittaker - 2023 - etheses.whiterose.ac.uk
Delayed left ventricular remodelling and optimal medical therapy in patients with heart failure
with reduced ejection fraction. Page 1 Laurence William Whittaker – MSc by thesis – HYMS …
with reduced ejection fraction. Page 1 Laurence William Whittaker – MSc by thesis – HYMS …
Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF …
P Żelazny, J Filipczak, O Sygacz, S Bróż… - Journal of Education …, 2022 - apcz.umk.pl
Introduction: Heart failure affects an estimated 23 million people, as many as 50% of whom
suffer from a heart failure with reduced ejection fraction (HFrEF), in which the left ventricle …
suffer from a heart failure with reduced ejection fraction (HFrEF), in which the left ventricle …